22902-87-0

Basic information

• Product Name: 2-Chloro-5-trifluoromethylbenzyl chloride
• Synonyms: 1-chloro-2-(chloromethyl)-4-(trifluoromethyl)benzene
• CAS NO: 22902-87-0
• Molecular Formula: C₈H₅Cl₂F₃
• Molecular Weight: 229.0265096
• Mol File: 22902-87-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-5-trifluoromethylbenzyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-trifluoromethylbenzyl chloride(22902-87-0)
• EPA Substance Registry System: 2-Chloro-5-trifluoromethylbenzyl chloride(22902-87-0)

Safety Data

• Hazardous Substances Data: 22902-87-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-trifluoromethylbenzyl chloride is used as a versatile building block for the preparation of various pharmaceuticals. Its unique functional groups allow for the synthesis of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-5-trifluoromethylbenzyl chloride serves as an intermediate in the production of various agrochemicals. Its properties make it suitable for the synthesis of compounds used in pest control and crop protection, enhancing agricultural productivity and sustainability.
Used in Dye Production:
2-Chloro-5-trifluoromethylbenzyl chloride is used as an intermediate in the production of dyes. Its functional groups enable the creation of dyes with specific color properties, making it valuable in the textile, printing, and other industries that rely on colorants.
Used in Polymer Synthesis:
2-Chloro-5-trifluoromethylbenzyl chloride is also utilized in the synthesis of polymers. Its presence in the polymer backbone can impart specific characteristics to the resulting polymer, such as improved stability or enhanced properties for specific applications.
Used in Specialty Chemicals Production:
2-Chloro-5-trifluoromethylbenzyl chloride is used as an intermediate in the production of various specialty chemicals. Its unique structure and functional groups make it a valuable component in the synthesis of advanced materials for diverse applications, including coatings, adhesives, and sealants.

Upstream product

• 121-50-6 3-amino-4-chlorobenzotrifluoride 
• 82386-89-8 2-chloro-5-(trifluoromethyl)benzaldehyde 
• 50-00-0 formaldehyd 
• 98-56-6 4-chlorobenzotrifluoride 
• 64372-62-9 (2-chloro-5-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 805-67-4 1-<2-Chlor-5-trifluormethyl-phenyl>-2-<4-methoxy-phenyl>-2-phenyl-aethylen 
• 64372-62-9 (2-chloro-5-(trifluoromethyl)phenyl)methanol 
• 82386-89-8 2-chloro-5-(trifluoromethyl)benzaldehyde 

Relevant articles and documents

A 2-halo-5-trifluoromethylbenzoate methyl animal pen alcoholic compound preparation method

The invention relates to the field of a medical intermediate, and particularly discloses a preparation method of intermediate 2-halogenate-5-trifluoromethyl benzyl alcohol of a novel cholesterol-lowering medicament, namely a cholesteryl ester transfer protein (CETP) inhibitor. The method comprises the following steps: carrying out chloromethylation reaction and esterification reaction on 4-halogenated trifluorotoluene used as a raw material, and then carrying out hydrolysis reaction so as to obtain a product 2-halogenate-5-trifluoromethyl benzyl alcohol compound. The method disclosed by the invention is available in raw materials, low in cost, environment-friendly and energy-saving, simple in process, easy for realization of industrialization, high in product yield, good in purity and stable in quality, and completely accords with the operating requirements on the medical intermediate.

Synthesis of stable isotope labeled anacetrapib, its major metabolites and [14C]anacetrapib

Cholesteryl ester transfer protein inhibitors are an important class of compounds designed to treat hypocholesterolemia and prevent cardiovascular disease. Anacetrapib (MK-0859) is currently in phase III trials for the treatment of elevated cholesterol levels and prevention of cardiovascular disease. In order to further support the development of anacetrapib, we prepared [M + 6]MK-0859, which was required in support of an absolute bioavailability study of the active pharmaceutical ingredient (API). Additional support included the synthesis of an internal standard [M + 13] and three stable isotope labeled metabolites, which were used to analyze clinical samples, and [ 14C]MK-0859 to support drug metabolism studies. A labeling strategy for the preparation of [M + 6], [M + 13], and [14C]anacetrapib is described. The preparation of stable isotope labelled metabolites of anacetrapib is also described.